Adaptimmune Therapeutics Plc logo

Adaptimmune Therapeutics Plc (ADAP) live share price

Adaptimmune Therapeutics Plc share price in USD $0.72 & INR ₹60.98

$0.72

View live Adaptimmune Therapeutics Plc share price in Dollar and Rupees. Guide to invest in Adaptimmune Therapeutics Plc from India. Also see the sentimental analysis on Indian investors investing in Adaptimmune Therapeutics Plc. Get details on the Indian mutual funds that are investing in Adaptimmune Therapeutics Plc. Get Analyst recommendations and forecasts along with all the Adaptimmune Therapeutics Plc's financials.

Adaptimmune Therapeutics Plc share price movements

  • $0.70
    $0.74

    Day's Volatility :5.34%

  • $0.43
    $2.05

    52 Weeks Volatility :79.02%

Adaptimmune Therapeutics Plc Returns

PeriodAdaptimmune Therapeutics PlcSector (Health Care)Index (Russel 2000)
3 Months
-40.44%
-6.2%
0.0%
6 Months
-28.64%
2.6%
0.0%
1 Year
36.34%
11.8%
0.0%
3 Years
-79.92%
13.3%
-19.8%

Adaptimmune Therapeutics Plc Key Statistics

in dollars & INR

Market Capitalization
$185.5M
Revenue TTM
$141.5M
EBITDA
$-72.9M
Earnings Per Share (EPS)
$-0.17
Profit Margin
-51.25%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-65.04%

How to invest in Adaptimmune Therapeutics Plc from India?

It is very easy for Indian residents to invest directly in Adaptimmune Therapeutics Plc from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Adaptimmune Therapeutics Plc stock in both rupees (INR) and dollars (USD). Search for Adaptimmune Therapeutics Plc or ADAP on INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Adaptimmune Therapeutics Plc or Rupee/ Dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Adaptimmune Therapeutics Plc shares which would translate to 1.176 fractional shares of Adaptimmune Therapeutics Plc as of today. Learn more about fractional investing here.

Indians via INDmoney can now also, easily transfer and add their money to the US stocks account via INDmoney App. Click here for step by step process for the same

Indian investors sentiment towards Adaptimmune Therapeutics Plc

108%

Period: Sep 3, 2024 to Dec 2, 2024. Change in 30 Days versus previous period

Search volume for Adaptimmune Therapeutics Plc on INDmoney from India has grown in the last 30 days as on Dec 3, 2024. 108% more investors are searching Adaptimmune Therapeutics Plc in the last 30 days versus the previous period.

Global Institutional Holdings in Adaptimmune Therapeutics Plc

  • Matrix Capital Management Company, LLC

    14.73%

  • EcoR1 Capital, LLC

    10.71%

  • NEA Management Company, LLC

    6.67%

  • Baillie Gifford & Co Limited.

    6.56%

  • Long Focus Capital Management, LLC

    5.20%

  • Partner Fund Management LP

    3.91%

Analyst Recommendation on Adaptimmune Therapeutics Plc

Buy

    69%Buy

    23%Hold

    7%Sell

Based on 13 Wall street analysts offering stock ratings for Adaptimmune Therapeutics Plc(by analysts ranked 0 to 5 stars)

Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
8
Hold
3
3
4
Sell
1
1
1

Analyst Forecast on Adaptimmune Therapeutics Plc

What analysts predicted

Upside of 214.82%

Current:

$0.72

Target:

$2.27

Insights on Adaptimmune Therapeutics Plc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 128.23M → 40.90M (in $), with an average decrease of 68.1% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 69.52M → -17.61M (in $), with an average decrease of 125.3% per quarter

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 47.6% return, outperforming this stock by 14.7%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 38.4% return, outperforming this stock by 119.1%

Adaptimmune Therapeutics Plc Financials in INR & Dollars

FY18Y/Y Change
Revenue
$59.5M
↑ 57.28%
Net Income
$-95.5M
↑ 36.18%
Net Profit Margin
-160.51%
↑ 24.88%
FY19Y/Y Change
Revenue
$1.1M
↓ 98.11%
Net Income
$-137.2M
↑ 43.61%
Net Profit Margin
-12.2K%
↓ 12064.53%
FY20Y/Y Change
Revenue
$4.0M
↑ 252.76%
Net Income
$-130.1M
↓ 5.16%
Net Profit Margin
-3.3K%
↑ 8938.23%
FY21Y/Y Change
Revenue
$6.1M
↑ 55.36%
Net Income
$-158.1M
↑ 21.52%
Net Profit Margin
-2.6K%
↑ 715.82%
FY22Y/Y Change
Revenue
$27.1M
↑ 341.5%
Net Income
$-165.5M
↑ 4.66%
Net Profit Margin
-609.46%
↑ 1961.53%
FY23Y/Y Change
Revenue
$60.3M
↑ 122.05%
Net Income
$-113.9M
↓ 31.18%
Net Profit Margin
-188.9%
↑ 420.56%
Q2 FY23Q/Q Change
Revenue
$5.1M
↓ 89.22%
Net Income
$-21.4M
↓ 2164.58%
Net Profit Margin
-416.94%
↓ 419.12%
Q3 FY23Q/Q Change
Revenue
$7.3M
↑ 42.67%
Net Income
$-45.6M
↑ 113.2%
Net Profit Margin
-623.05%
↓ 206.11%
Q4 FY23Q/Q Change
Revenue
$233.0K
↓ 96.82%
Net Income
$-48.3M
↑ 5.99%
Net Profit Margin
-20.7K%
↓ 20120.28%
Q1 FY24Q/Q Change
Revenue
$5.7M
↑ 2336.82%
Net Income
$-48.5M
↑ 0.35%
Net Profit Margin
-854.23%
↑ 19889.1%
Q2 FY24Q/Q Change
Revenue
$128.2M
↑ 2158.38%
Net Income
$69.5M
↓ 243.33%
Net Profit Margin
54.22%
↑ 908.45%
Q3 FY24Q/Q Change
Revenue
$40.9M
↓ 68.1%
Net Income
$-17.6M
↓ 125.34%
Net Profit Margin
-43.07%
↓ 97.29%
FY18Y/Y Change
Total Assets
$276.7M
↓ 1.57%
Total Liabilities
$29.9M
↓ 61.81%
FY19Y/Y Change
Total Assets
$181.5M
↓ 34.4%
Total Liabilities
$57.9M
↑ 93.98%
FY20Y/Y Change
Total Assets
$451.1M
↑ 148.5%
Total Liabilities
$109.9M
↑ 89.82%
FY21Y/Y Change
Total Assets
$469.5M
↑ 4.08%
Total Liabilities
$263.6M
↑ 139.81%
FY22Y/Y Change
Total Assets
$328.9M
↓ 29.95%
Total Liabilities
$247.0M
↓ 6.28%
FY23Y/Y Change
Total Assets
$282.6M
↓ 14.08%
Total Liabilities
$243.1M
↓ 1.59%
Q2 FY23Q/Q Change
Total Assets
$343.0M
↑ 19.06%
Total Liabilities
$216.3M
↑ 5.94%
Q3 FY23Q/Q Change
Total Assets
$296.6M
↓ 13.51%
Total Liabilities
$208.5M
↓ 3.62%
Q4 FY23Q/Q Change
Total Assets
$282.6M
↓ 4.73%
Total Liabilities
$243.1M
↑ 16.59%
Q1 FY24Q/Q Change
Total Assets
$258.0M
↓ 8.71%
Total Liabilities
$233.6M
↓ 3.89%
Q2 FY24Q/Q Change
Total Assets
$321.7M
↑ 24.69%
Total Liabilities
$225.4M
↓ 3.51%
Q3 FY24Q/Q Change
Total Assets
$317.4M
↓ 1.33%
Total Liabilities
$237.4M
↑ 5.33%
FY18Y/Y Change
Operating Cash Flow
$-104.4M
↑ 92.19%
Investing Cash Flow
$-17.5M
↓ 86.15%
Financing Cash Flow
$102.7M
↓ 0.85%
FY19Y/Y Change
Operating Cash Flow
$-112.5M
↑ 7.78%
Investing Cash Flow
$94.9M
↓ 643.88%
Financing Cash Flow
$366.0K
↓ 99.64%
FY20Y/Y Change
Operating Cash Flow
$-53.6M
↓ 52.37%
Investing Cash Flow
$-278.9M
↓ 393.77%
Financing Cash Flow
$340.1M
↑ 92810.11%
FY21Y/Y Change
Operating Cash Flow
$10.7M
↓ 120.02%
Investing Cash Flow
$75.8M
↓ 127.18%
Financing Cash Flow
$3.3M
↓ 99.03%
FY22Y/Y Change
Operating Cash Flow
$-141.8M
↓ 1421.36%
Investing Cash Flow
$89.1M
↑ 17.59%
Financing Cash Flow
$12.9M
↑ 291.33%
Q2 FY23Q/Q Change
Operating Cash Flow
$-43.8M
↑ 17.38%
Investing Cash Flow
$2.7M
↑ 0.0%
Financing Cash Flow
$14.0K
↓ 92.86%
Q3 FY23Q/Q Change
Operating Cash Flow
$-45.2M
↑ 3.19%
Investing Cash Flow
$57.3M
↑ 2027.17%
Financing Cash Flow
$596.0K
↑ 4157.14%

Adaptimmune Therapeutics Plc Technicals Summary

Sell

Neutral

Buy

Adaptimmune Therapeutics Plc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Adaptimmune Therapeutics Plc Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Adaptimmune Therapeutics Plc
Adaptimmune Therapeutics Plc
-12.91%
-28.64%
36.34%
-79.92%
-36.78%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-9.49%
-24.47%
-8.88%
20.04%
103.68%
Biontech Se
Biontech Se
8.64%
19.01%
18.5%
-57.69%
426.41%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-6.25%
68.98%
46.39%
42.98%
103.71%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-0.99%
-1.44%
33.51%
128.29%
109.86%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Adaptimmune Therapeutics Plc
Adaptimmune Therapeutics Plc
NA
NA
0.11
-0.14
-0.65
-0.16
NA
0.17
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
18.55
18.66
1.12
44.91
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-3.06
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.19
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.22
0.54
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Adaptimmune Therapeutics Plc
Adaptimmune Therapeutics Plc
Buy
$185.5M
-36.78%
NA
-51.25%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$83.0B
103.68%
18.55
33.61%
Biontech Se
Biontech Se
Buy
$28.9B
426.41%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$32.7B
103.71%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.6B
109.86%
32.84
-4.51%

About Adaptimmune Therapeutics Plc

adaptimmune llc is a multinational, clinical-stage biopharmaceutical company focused on developing novel immunotherapies using its proprietary t-cell receptor platform that has the potential to transform the treatment of cancer. established in 2008, the company has grown from being privately held to one of the most successful biopharmaceutical initial public offerings (ipo) in 2015. with u.s. operations based in philadelphia, pa, adaptimmune is a company founded on strong science that has led to a robust pipeline of immuno-oncology product candidates, a growing research & development platform and ongoing plans for expansion. for more information about adaptimmune, please visit www.adaptimmune.com. if interested in joining our fast growing team, click on the careers tab of this page.
Organization
Adaptimmune Therapeutics Plc
Employees
449
CEO
Mr. Adrian G. Rawcliffe
Industry
Health Technology

Important FAQs about investing in Adaptimmune Therapeutics Plc from India :

What is Adaptimmune Therapeutics Plc share price today?

Adaptimmune Therapeutics Plc (ADAP) share price today is $0.72.

Can Indians buy Adaptimmune Therapeutics Plc shares?

Yes, Indians can invest in the Adaptimmune Therapeutics Plc (ADAP) from India.

With INDmoney, you can buy Adaptimmune Therapeutics Plc at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Adaptimmune Therapeutics Plc at zero transaction cost.

How can I buy Adaptimmune Therapeutics Plc shares from India?

It is very easy to buy Adaptimmune Therapeutics Plc from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Adaptimmune Therapeutics Plc be purchased?

Yes, you can buy fractional shares of Adaptimmune Therapeutics Plc with INDmoney app.

What are the documents required to start investing in Adaptimmune Therapeutics Plc stocks?

To start investing in Adaptimmune Therapeutics Plc, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Adaptimmune Therapeutics Plc

Today’s highest price of Adaptimmune Therapeutics Plc (ADAP) is $0.74.

Today’s lowest price of Adaptimmune Therapeutics Plc (ADAP) is $0.70.

What is today's market capitalisation of Adaptimmune Therapeutics Plc

Today's market capitalisation of Adaptimmune Therapeutics Plc ADAP is 185.5M

What is the 52 Week High and Low Range of Adaptimmune Therapeutics Plc

  • 52 Week High

    $2.05

  • 52 Week Low

    $0.43

How much percentage Adaptimmune Therapeutics Plc is down from its 52 Week High?

Adaptimmune Therapeutics Plc (ADAP) share price is $0.72. It is down by 99% from its 52 Week High price of $2.05.

How much percentage Adaptimmune Therapeutics Plc is up from its 52 Week low?

Adaptimmune Therapeutics Plc (ADAP) share price is $0.72. It is up by 1% from its 52 Week Low price of $0.43.

What are the historical returns of Adaptimmune Therapeutics Plc?

  • 1 Month Returns

    -12.91%

  • 3 Months Returns

    -28.64%

  • 1 Year Returns

    36.34%

  • 5 Years Returns

    -36.78%

Who is the Chief Executive Officer (CEO) of Adaptimmune Therapeutics Plc

Mr. Adrian G. Rawcliffe is the current Chief Executive Officer (CEO) of Adaptimmune Therapeutics Plc.